Pexidartinib通过影响小鼠小胶质细胞和神经炎症缓解神经病理性疼痛
该研究在小鼠慢性压迫性损伤(CCI)模型中,每日口服PLX-3397或溶媒共21天,造模后再给药28天,发现PLX-3397显著改善疼痛相关行为,并减少小胶质细胞及神经炎症标志物,提示其作为镇痛药的潜力。
要点
- PLX-3397在CCI小鼠中持续改善疼痛相关行为。
- PET神经影像和免疫荧光显示PLX-3397减少小胶质细胞。
- PLX-3397降低iNOS等神经炎症相关蛋白表达。
核心结论
- PLX-3397通过减少小胶质细胞和神经炎症减轻小鼠神经病理性疼痛。
- 研究为测试PLX-3397作为镇痛药提供了新的概念验证数据。
研究设计与样本
- 使用CCI小鼠模型,PLX-3397或溶媒每日口服21天,造模后再给药28天。
- 采用PET神经影像和免疫荧光/免疫组化检测小胶质细胞及神经炎症标志物。
临床怎么用
- PLX-3397为FDA已批准抗癌药及CSF-1R抑制剂,具有小胶质细胞耗竭特性。
- 该研究为临床前证据,支持进一步评估PLX-3397作为镇痛药的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic pain is a debilitating medical condition that lacks effective treatments. Increasing evidence suggests that microglia and neuroinflammation underlie pain pathophysiology, which therefore supports a potential strategy for developing pain therapeutics. Here, our study is testing the hypothesis that the promise of pain amelioration can be achieved using the small-molecule pexidartinib (PLX-3397), a previously food and drug administration (FDA)-approved cancer medicine and a colony-stimulating factor-1 receptor (CSF-1R) inhibitor that display microglia-depleting properties. METHOD: We used the previously reported chronic constriction injury (CCI) mouse model, in which PLX-3397 or vehicle was orally administrated to mice daily for 21 days, then applied to the CCI model, followed by PLX-3397 or vehicle administration for an additional 28 days. Additionally, we examined microglia-related neuroinflammation markers using positron emission tomography (PET) neuroimaging and immunofluorescence (IF). RESULTS: We showed that PLX-3397 significantly ameliorated pain-related behavioral changes throughout the entire experimental period after CCI (vehicle versus PLX-3397 at day 14, effect size: 2.57, P = .002). Microglia changes were first analyzed by live-animal PET neuroimaging, revealing PLX-3397-associated reduction of microglia by probing receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a protein primarily expressed in microglia, which were further corroborated by postmortem immunohistochemistry (IHC) analysis using antibodies for microglia, including ionized Ca 2+ binding adaptor molecule 1 (Iba-1) (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size 3.6, P = .011) and RIPK1 (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size 2.9, P = .023. The expression of both markers decreased in the PLX-3397 group. Furthermore, we found that PLX-3397 led to significant reductions in various proteins, including inducible nitric oxide synthase (iNOS) (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size: 2.3, P = .048), involved in neuroinflammation through IHC. CONCLUSIONS: Collectively, our study showed PLX-3397-related efficacy in ameliorating pain linked to the reduction of microglia and neuroinflammation in mice. Furthermore, our research provided new proof-of-concept data supporting the promise of testing PLX-3397 as an analgesic.
引用
- Yang L, Gomm A, Bai P, et al. The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice. Anesth Analg. 2024. PMID: 39475839. doi:10.1213/ANE.0000000000007239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。